

Medibio Limited (ASX: MEB)

Medibio Limited (ASX: MEB) (“Medibio” or “the Company”) is pleased to report on its activities for the June 2015 quarter.

Highlights

- University of New South Wales/Black Dog Institute trial begins
 - o Study expected to be complete and results published by end of 2015
 - Medibio successfully validates world’s first stress test based on Circadian Heart Rate technology
 - o Development of a corporate stress App expected to be complete in September Quarter
 - o Discussions with potential corporate clients underway
 - Medibio signs MOU with Preventice Solutions
 - Appointment of Dr Franklyn Prendergast, a current Eli Lilly Board member, to Medibio’s Advisory Board
 - \$1.4 million R&D rebate to be received during the current quarter
-

University of New South Wales/Black Dog Institute trial begins

The first pivotal study of Medibio’s CHR technology, being conducted by the University of New South Wales (UNSW) and the Black Dog Institute (BDI), processed its first participant during the quarter. Medibio expects all of the 80 planned participants to have completed assessment by the end of the September quarter, and the study completed, with results published before the end of 2015.

The study is designed to demonstrate that MEB’s Circadian Heart Rate Variability (CHR-V) technology is the first objective diagnostic tool able to distinguish between the two subsets of depression: melancholic and non-melancholic depression. The study will also involve serial monitoring of the participants before and after treatment to validate the technology’s use as an objective measure to determine the effectiveness of the treatment.

Stress test validated

Medibio produced and validated the world’s first evidence-based test to measure stress levels and its impact on health and wellbeing using its own Circadian Heart Rate (CHR) technology. A series of new algorithms has been developed to measure the type and degree of deviation of the subject’s CHR from normal and the diagnostic significance of this deviation. The critical period for monitoring CHR is the sleep period when external influences are absent, providing an accurate measure of the impact of stress. Medibio’s new algorithms accurately classify individuals into one of three categories based on the impact stress has had on their health and wellbeing, being:

1. Normal to mild: Where no immediate action needed
2. Moderate: The impact of stress is approaching unhealthy levels
3. Serious: Stress has had an unhealthy impact and lifestyle changes are recommended

Medibio Limited (ASX: MEB)

Internal validation testing returned excellent results with sensitivities and specificities in excess of 80% for correctly assessing the subject into one of these three stress categories. This compares favourably to the diagnostic accuracy of traditional self-report questionnaires for assessing stress levels which are typically in the 40-60% range.

There are significant benefits to Medibio and potential markets in successfully commercialising the test.

Medibio is porting the new stress algorithms into a cloud based environment, where they will run on commercial scale, in parallel with the completion of its corporate stress product including an App based intervention tailored to the assessed level. This is anticipated to be completed in the coming quarter to allow the commercial launch of an end to end solution for assessing and combating stress in the workplace. The company is also working with a number of ECG device manufacturers who want to ensure that their monitors are compatible with Medibio's stress assessment product.

The company will continue discussions with potential customers of the App ahead of the commercial launch.

MOU with Preventice Solutions

During the quarter, Medibio entered a Memorandum of Understanding (MOU) with Preventice Solutions (Preventice Inc.). Preventice Solutions is a strategic combination of: eCardio Diagnostics® LLC, a leading provider of remote cardiac monitoring products and services, and Preventice, an innovator in software solutions for remote patient care and developer of the PatientCare Platform and the BodyGuardian® Remote Monitoring Sensor. The two US companies operate as wholly-owned subsidiaries of a newly formed holding company, Preventice Inc.

Preventice Solution's health data platform is ideal for the commercial delivery of Medibio's Circadian Heart Rate tests to assist clinicians with the diagnosis of depression, workplace stress, and other mental health disorders. Additionally, Preventice Solutions has significant infrastructure in the US including an end to end sales and distribution chain to providers and leading medical organisations and a 24/7 patient call centre which could potentially be leveraged by Medibio.

The MOU provides a framework for how both parties could collaborate which may lead towards a Strategic Partnership Agreement. The MOU outlines the contemplated aspects of a Definitive Agreement.

Corporate

During the quarter the company continued to strengthen its medical team with the appointment of Dr Franklyn Prendergast to its advisory Board. Dr Prendergast is the former director for research at Mayo Clinic as well as being a member of the Board of Governors for Mayo Clinic, Rochester. Dr Prendergast has been a member of the Eli Lilly Company Board of Directors since 1995. He served extensively for the National Institutes of Health (NIH) on numerous study section review groups. Dr Prendergast's reputation and experience within US healthcare, especially clinical research and healthcare policy, brings tremendous gravitas to Medibio Limited's technology and strategy.

ASX Market Update



Medibio Limited (ASX: MEB)

During the quarter the company moved much of its budgeted expenditure forward into the current quarter. This was done to fast track development however it also allowed this expenditure to be expensed in the current financial year. This will see the company receive an estimated \$1.4 million R&D rebate in the current quarter. This will return the company's cash position back towards \$2 million and sees Medibio funded for the next 12 months.

About Medibio Limited

Medibio (ASX: MEB) is a medical technology company developing a new objective test to assist in the diagnosis of depression and other mental health disorders and chronic stress. This test utilises circadian heart rate variability. The technology is based on measured differences in circadian heart rate and measures of heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression, other mental health disorders and chronic stress. The technology consists of a heart monitor that sends ECG recordings wirelessly to the internet where a proprietary algorithm analyses and delivers a quantifiable measure which can be used by a clinician to assist in diagnosis. The Technology has the potential to be the first FDA Approved objective, evidence based approach to the diagnosis of depression and other mental health disorders. The technology has already benefited from 10 years of laboratory research and Medibio is undertaking a number of pivotal studies to validate its clinical utility.

Further Information:	
Medibio Shareholder Enquiries: Kris Knauer Executive Director: Medibio Limited kris.knauer@Medibio.com.au T: +61 (0)411 885 979	Medibio Investor Relations: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231